我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

Salusin-β对缺血/再灌注心肌损伤的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第5期
页码:
648-651
栏目:
基础研究
出版日期:
2009-07-14

文章信息/Info

Title:
Effects of salusin-β on heart ischemia-reperfusion injury
作者:
王键飞1; 周旭1; 印媛君2; 袁文俊1; 3; 林丽3; 任安经3
1.宁夏医科大学生理学教研室,宁夏 银川 750004；2.浙江中医药大学生理学 教研室，浙江 杭州 310053；3.第二军医大学生理学教研室，上海 200433
Author(s):
WANG Jian-fei1;  ZHOU Xu1;  YIN Yuan-jun2;  YUAN Wen-jun1; 3;  LIN Li3;  REN An-jing3
1.Department of Physiology, Ningxia Medical University, Yinchuan 750004, Ningxia, China; 2.Department of Physiology, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China; 3.Department of Physiology, Second Military Medical University, Sha
关键词:
salusin-β; 心脏; 缺血/再灌注; 大鼠
Keywords:
salusin-β;  heart;  ischemia;  reperfusion
分类号:
R322.11
DOI:
-
文献标识码:
A
摘要:
目的: 探明salusin-β——一种新发现的心血管调节肽是否具有抗心肌缺血/再灌损伤(RMMI)的作用。方法: 以离体灌流大鼠的心脏RMMI为模型，分为对照组和salusin-β预处理组，观察各组大鼠心脏缺血/再灌注(I/R)后的心率(HR)、冠脉流量(CF)和心功能［左室收缩压(LVSP)、左室舒张末压(LVEDP)和左室内压上升、下降速率（±dp/dt）］的变化。结果: 以10-8 mol/L的salusin-β预处理，可以改善心脏I/R后CF、LVDP、LVEDP、+dp/dt和-dp/dt等指标。10-8 mol/L salusin-β组复灌30 min时，CF、LVDP、+dp/dt和-dp/dt的恢复率，分别是停灌前的（52±5）%、（79±8）%、（70±8）%和（69±10）%，显著高于对照组的（45±6）%、（68±10）%、（58±11）%和（57±8）%（P<0.01，n=8）。此外，10-8 mol/L salusin-β组复灌30 min时，LVEDP为(28.25±7.62)mmHg，显著低于对照组的(52.52±11.27)mmHg。结论: 上述结果表明，salusin-β具有抗心肌RMMI、改善I/R后心脏功能的作用。
Abstract:
AIM: To investigate whether salusin-β, a new regulatory peptide relevant to the cardiovascular system, can alleviate heart ischemia-reperfusion injury. METHODS: The effects of salusin-β on heart rate (HR), coronary flow (CF) and heart function (LVSP, LVEDP and ±dp/dt) were observed in isolated rat hearts after ischemia-reperfusion. RESULTS: Treatment with 10-8 mol/L salusin-β significantly improved the post-ischemic CF, LVDP, LVEDP and ±dp/dt compared with those of the untreated hearts. The recovery of CF, LVDP, +dp/dt and dp/dt after reperfusion for 30 min was, respectively, (52±5)%, (79±8)%, (70±8)% and (69±10)% vs. (45±6)%, (68±10)%, (58±11)% and (57±8)% in control group (P<0.01, n=8). In addition, in the presence of 10-8 mol/L salusin-β, LVEDP (28.25±7.62)mmHg improved significantly compared with that in control group (52.52±11.27)mmHg. CONCLUSION: These results show that salusin-β alleviates ischemia-reperfusion injury and improves heart function.

参考文献/References

［1］ Shichiri M, Ishimaru S, Ota T, et al. Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities［J］. Nat Med, 2003, 9(9):1166-1172.

［2］ Suzuki N, Shichiri M, Akashi T, et al. Systemic distribution of salusin expression in the rat ［J］. Hypertens Res, 2007, 30(12):1255-1262.

［3］ Izumiyama H, Tanaka H, Egi K, et al. Synthetic salusins as cardiac depressors in rat ［J］. Hypertension, 2005, 45(3):419-425.

［4］ Yu F, Zhao J, Yang J, et al. Salusins promote cardiomyocyte growth but does not affect cardiac function in rats［J］. Regul Pept, 2004, 122(3):191-197.

［5］ Takenoya F, Hori T, Kageyama H, et al. Coexistence of salusin and vasopressin in the rat hypothalamo-hypophyseal system［J］. Neurosci Lett, 2005, 385(2):110-113.

［6］ Xiao-Hong Y, Li L, Yan-Xia P, et al. Salusins protect neonatal rat cardiomyocytes from serum deprivation-induced cell death through upregulation of GRP78［J］. J Cardiovasc Pharmacol, 2006, 48(2):41-46.

［7］ Watanabe T, Nishio K, Kanome T, et al. Impact of salusin-alpha and -beta on human macrophage foam cell formation and coronary atherosclerosis［J］. Circulation, 2008, 117(5):638-648.

［8］ Watanabe T, Suguro T, Sato K, et al. Serum salusin-alpha levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients［J］. Hypertens Res, 2008, 31(3):463-468.

［9］ Di Lisa F. Mitochondrial contribution in the progression of cardiac ischemic injury［J］. IUBMB Life, 2001, 52(3-5):255-261.

［10］Ferrari R, Guardigli G, Mele D, et al. Oxidative stress during myocardial ischaemia and heart failure［J］. Curr Pharm Des, 2004, 10(14):1699-1711.

［11］Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury［J］. Physiol Rev, 2008, 88(2):581-609.

［12］Hayashi H. Pathogenesis and the role of Ca2+ overload during myocardial ischemia/reperfusion［J］. Nagoya J Med Sci, 2000, 63(3-4):91-98.

［13］Galagudza MM, Blokhin IO, Shmonin AA, et al. Reduction of myocardial ischemia-reperfusion injury with pre- and postconditioning: molecular mechanisms and therapeutic targets［J］. Cardiovasc Hematol Disord Drug Targets, 2008, 8(1):47-65.

［14］Yamamoto S, Matsumoto N, Kanazawa M, et al. Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts［J］. Circulation, 2005, 111(3):302-309.

［15］Baker CS, Kumar S, Rimoldi OE. Effects of brief ischemia and reperfusion on the myocardium and the role of nitric oxide［J］. Heart Fail Rev, 2003, 8(2):127-141.

［16］Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury ［J］. Cardiovasc Res, 1999, 43(4):860-878.

备注/Memo

备注/Memo:
收稿日期：2008-11-21.基金项目：国家自然科学基金项目资助（30600763和30800375） 通讯作者：任安经，讲师，博士，主要从事心血管生理学的研究Email:renanjing2008@yahoo.com.cn 作者简介：王键飞，硕士生Email:flycatcoffee66@hotmail.com
更新日期/Last Update: 2009-07-22